Ianevski, A.; Yao, R.; Lysvand, H.; Grødeland, G.; Legrand, N.; Oksenych, V.; Zusinaite, E.; Tenson, T.; Bjørås, M.; Kainov, D.E.
Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2. Viruses 2021, 13, 1768.
https://doi.org/10.3390/v13091768
AMA Style
Ianevski A, Yao R, Lysvand H, Grødeland G, Legrand N, Oksenych V, Zusinaite E, Tenson T, Bjørås M, Kainov DE.
Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2. Viruses. 2021; 13(9):1768.
https://doi.org/10.3390/v13091768
Chicago/Turabian Style
Ianevski, Aleksandr, Rouan Yao, Hilde Lysvand, Gunnveig Grødeland, Nicolas Legrand, Valentyn Oksenych, Eva Zusinaite, Tanel Tenson, Magnar Bjørås, and Denis E. Kainov.
2021. "Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2" Viruses 13, no. 9: 1768.
https://doi.org/10.3390/v13091768
APA Style
Ianevski, A., Yao, R., Lysvand, H., Grødeland, G., Legrand, N., Oksenych, V., Zusinaite, E., Tenson, T., Bjørås, M., & Kainov, D. E.
(2021). Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2. Viruses, 13(9), 1768.
https://doi.org/10.3390/v13091768